Pharma BD Deal Intelligence
Bold bet on China speed: BMS pays Hengrui just $600M upfront for 13 oncology, hematology and immunology programs, with total value reaching $15.2B only if milestones across the multi-asset alliance actually land.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
BMS and Hengrui Pharma are building a 13-asset pipeline in a deal worth up to $15.2 billion across oncology, hematology and immunology. Hengrui contributes…
Bristol Myers Squibb is paying Chinese drugmaker Jiangsu Hengrui Pharmaceutical $600 million upfront with potential milestone payments that could push the…
Bristol Myers Squibb and Hengrui forge a $15.2 billion strategic alliance reshaping the China-out licensing landscape. The deal follows recent precedents…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS and Hengrui entered into a multi-asset strategic collaboration and license covering 13 early-stage programs (4 Hengrui oncology/hematology assets, 4 BMS immunology assets, 5 joint-discovery programs). BMS pays Hengrui $600M upfront, $175M first-anniversary, $175M contingent second-anniversary (i.e., up to $950M near-term), plus option-exercise fees and milestones bringing total potential value to ~$15.2B, plus tiered royalties. One of the largest pharma-China alliances on record.
2.0M US cases/yr · $250.0B 2024 global oncology + immunology drug market, IQVIA/EvaluatePharma
The 13-program portfolio spans solid tumors (HER2+, TNBC, NSCLC, gastric/CRC), hematologic malignancies, and chronic immunology indications (IBD, dermatology, rheumatology). Unmet need is differentiated by program: in oncology, biomarker-defined subtypes with limited targeted options; in immunology, patients failing JAK inhibitors and biologics seeking deeper remission with improved safety profiles.
BMS competes against Merck (Keytruda franchise + Daiichi/Sankyo ADC alliances), AstraZeneca/Daiichi (Enhertu, Datroway), Pfizer (Seagen ADCs), AbbVie (Skyrizi/Rinvoq immunology), J&J (Tremfya, Stelara/Carvykti) and Roche. The Hengrui deal is one of the largest China-out licensing transactions on record, following AbbVie/Hengrui, Merck/Hengrui and BioNTech/Biotheus and signals a structural shift toward sourcing early-stage assets from Chinese biotech to compress development timelines.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Jiangsu Hengrui Pharmaceuticals Co. Ltd. (this deal) | 2026 | $15.2B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2026 deals · Bristol-Myers Squibb Company deals · Hematology deals